UW Spin-Out Seeks to Develop Celiac Disease Therapy
SEATTLE and SAN DIEGO, Dec. 20, 2016 – PvP Biologics, a University of Washington spin-out, is advancing a scientifically designed enzyme that could help people with celiac disease. The UW Institute for...
View ArticlePvP Biologics Announces Leadership Team
SAN DIEGO and SEATTLE, January 5 – PvP Biologics today announced the company’s leadership team. The company was formed to advance an oral enzyme therapy, called KumaMax, for the treatment of celiac...
View ArticleTakeda and PvP Biologics Announce Development Agreement around Novel...
Osaka, Japan, January 6, 2017, San Diego, Calif., USA, and Seattle, Wash., USA, January 5, 2017 – Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502) and PvP Biologics, Inc. (“PvP”) today...
View ArticleIn the News: PvP Biologics and Takeda Deal
In a unique deal, PvP Biologics skipped venture funding and brought on pharma partner Takeda in a $35 million agreement to advance a therapeutic candidate, called KumaMax, for celiac disease into...
View ArticleOzy News: How Designer Proteins Could Change Your Life
Ozy News spoke with Drs. David Baker and Ingrid Swanson Pultz about using Rosetta, a computer software program, to design novel proteins, like KumaMax. KumaMax is a uniquely engineered, recombinant...
View ArticleSynbiobeta: PvP takes a nontraditional path to early stage drug development...
Winning iGEM award was just the beginning The KumaMax project got its start in 2011 as an undergraduate project at the University of Washington (UW) for the international Genetically Engineered Machine...
View ArticlePvP Biologics Announces First-in-Human Clinical Trials for a Novel...
SAN DIEGO and SEATTLE, September 6, 2018 – PvP Biologics, Inc. (“PvP”) today announced the initiation of two first-in-human clinical trials for Kuma062, a product candidate for the treatment of celiac...
View Article